Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Cenegermin in Pediatric Neurotrophic Keratopathy

Pedrotti, Emilio MD; Bonetto, Jacopo MD; Cozzini, Tiziano MD; Fasolo, Adriano MSc; Marchini, Giorgio MD

doi: 10.1097/ICO.0000000000002112
Case Report
Buy

Purpose: We report a case of neurotrophic keratopathy (NK) arising after surgery for rhabdomyosarcoma of the jaw successfully treated with Cenegermin eye drops (Oxervate; Dompé Farmaceutici, Milan, Italy) in a 3-year-old boy.

Methods: At the age of 1 year, the boy underwent surgery for rhabdomyosarcoma of the jaw, followed by radiotherapy. Subsequent NK was initially treated with preservative-free artificial tears, topical combination of dexamethasone 0.1% and netilmicin 0.3% (Netildex; Sifi, Catania, Italy), and moxifloxacin 0.5% (Vigamox; Alcon, Fort Worth, TX), followed by 10 cycles of a topical eye biopolymer containing a poly-carboxymethyl glucose sulfate solution (Cacicol; Theà, Clermont-Ferrand, France) and 4 amniotic membrane transplantations. Keratopathy was recalcitrant to therapy and tissue transplant. Therapy was switched to Cenegermin eye drops 6 times daily for 8 weeks.

Results: Complete healing of the corneal epithelium was achieved at 3 weeks into treatment.

Conclusions: Cenegermin was effective in restoring corneal integrity in this pediatric patient with NK.

Department of Neurosciences, Biomedicine and Movement Sciences, Eye Clinic, University of Verona, Verona, Italy.

Correspondence: Jacopo Bonetto, MD, Department of Neurosciences, Biomedicine and Movement Sciences, Eye Clinic, University of Verona, Policlinico G.B. Rossi, P.le L.A. Scuro 10, Verona 37134, Italy (e-mail: jacopobonetto@libero.it).

The authors have no funding or conflicts of interest to disclose.

Received December 08, 2018

Received in revised form June 19, 2019

Accepted July 05, 2019

Online date: August 8, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.